A Phase 2 interventional study of Fulvestrant and Anastrozole in Breast Cancer, sponsored by AstraZeneca. Completed at 25 sites in 3 countries. Open to female participants. Per ClinicalTrials.gov, last updated 2010-12-21.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.
Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 78th largest by enrollment of the 94 interventional ones that give a count, is one of 5 that started in 2006, is one of 59 in phase 2, and was the 24th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19–80 · Women only
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
University of California, Irvine · Sites in United States
Ages 18+
Prof. Wolfgang Janni · Sites in Germany, Switzerland
Ages 18+ · Women only
Royal Marsden NHS Foundation Trust · Sites in France, United Kingdom
Ages 18+
By country, each count listing its studies:
Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, fulvestrant is the treatment under test here. Read study by study →
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 63 · Phase 3 21 · Phase 4 4
First in 1997; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 71 across the 94 interventional studies. Of the 55 that completed or were terminated, 34 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 95 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 119th largest by enrollment of the 125 interventional ones that give a count, is one of 9 that started in 2006, is one of 31 in phase 2, and was the 34th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
7 of the studies testing fulvestrant in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01953588Phase 3Alliance for Clinical Trials in OncologyFulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | 2027-04-01 |
| NCT07163481Hunan Cancer HospitalA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | 2026-12 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT00585507Beth Israel Deaconess Medical CenterEfficacy and Safety of 500mg of Fulvestrant | 2027-03-15 |
| NCT05319873Jonsson Comprehensive Cancer CenterRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 95 studies testing fulvestrant in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
Purpose is to compare the frequency of events (presence of Disseminated Tumour Cells, clinical recurrence and/or death) after 1 and 2 years of adjuvant treatment with anastrozole and fulvestrant or anastrozole alone in patients with early breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anastrozole monotherapy
Drug: Anastrozole
Anastrozole + Fulvestrant
Drug: Fulvestrant · Drug: Anastrozole
intramuscular injection
Also known as: Faslodex, ZD9238
1 mg oral tablet
Also known as: Arimidex, ZD1033
Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence)
Number of patients event-free
Time frame: 12 month period following randomisation
| Milestone | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|
| Started | 6 | 7 |
| Completed | 1 | 2 |
| Not completed | 5 | 5 |
| Withdrew: Early study termination | 5 | 5 |
Number of patients event-free
| Participants | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|
| Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence) | 6 | 7 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fulvestrant + Anastrozole | — | 1/6 (16.7%) | 5/6 (83.3%) |
| Anastrozole | — | 2/7 (28.6%) | 5/7 (71.4%) |
| Event | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|
| Varicose VeinVascular disorders | 1/6 | 0/7 |
| GoitreEndocrine disorders | 0/6 | 1/7 |
| Haemorrhoid OperationGastrointestinal disorders | 0/6 | 1/7 |
| SciaticaNervous system disorders | 0/6 | 1/7 |
| Renal FailureRenal and urinary disorders | 0/6 | 1/7 |
| Event | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|
| InsomniaPsychiatric disorders | 3/6 | 0/7 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/6 | 2/7 |
| FlushingVascular disorders | 2/6 | 1/7 |
| Unevaluable EventGeneral disorders | 2/6 | 1/7 |
| AnorexiaMetabolism and nutrition disorders | 2/6 | 0/7 |
| Back PainMusculoskeletal and connective tissue disorders | 1/6 | 0/7 |
| Muscular WeaknessMusculoskeletal and connective tissue disorders | 1/6 | 0/7 |
| Musculoskeletal Chest PainMusculoskeletal and connective tissue disorders | 1/6 | 0/7 |
| Hot FlushVascular disorders | 1/6 | 1/7 |
| FatigueGeneral disorders | 1/6 | 1/7 |
| Age Continuous(age in years at baseline) | Fulvestrant + Anastrozole | Anastrozole | Total |
|---|---|---|---|
| Mean | 60.5 ± 5.4 | 63.4 ± 3.5 | 62.1 ± 4.5 |
| Sex: Female, Male(Participants) | Fulvestrant + Anastrozole | Anastrozole | Total |
|---|---|---|---|
| Female | 6 | 7 | 13 |
| Male | 0 | 0 | 0 |
The record gives a start of Apr 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fulvestrant